Update on Drug-Eluting Balloons for Percutaneous Coronary Interventions

Beatriz Vaquerizo, Dabit Arzamendi Aizpurua, Juan Cinca Cuscullida, Antonio Serra Penaranda

Interventional Cardiology Unit, Department of Cardiology, Hospital Sant Pau, Barcelona, Spain

Disclosure: Produced on behalf of the Healthy Cath Lab (HCL) Study Group of the Italian Society of
Invasive Cardiology (GISE).
Citation: EMJ Int Cardiol. 2013;1:80-90.


With the aim to overcome the limitations of DES, a new concept of coronary intervention has been introduced in the recent years, the use of drug-eluting balloons (DEB). Paclitaxel coated-balloon (PCB) angioplasty appeared with the objective to achieve a local and homogeneous high concentration of an antiproliferative agent at the site of endovascular interventions. Advantages of this approach over the use of DES include a more homogeneous drug distribution and the fact that this mode of local delivery does not require foreign material implantation. Moreover, the recently introduced concept of “combined treatment strategy” of bare metal stent followed by DEB has aroused the interest of interventional cardiologist. Therefore the information that has emerged ina short time has been incredible. This review provides an up-to-date on drug-eluting balloons (DEB). We analyse in detail the DEB commercially available, including essential data about drug transfer and the formulation used to coat the balloon. Moreover, first clinical experiences with DEB in different scenario are reminded in detail.

Download (PDF, 711KB)

Leave a Reply